Formulary Watch |

Based on reports from post-marketing experience, Spravato’s warnings and precautions section now includes the risk of respiratory depression.

The mean lag time between FDA approval and insurance coverage for 89 cancer drugs ranged from 2.3 months to 8.2 months. But cancer drugs approved more recently were more likely to have shorter coverage lags.

In new data, 60% of the patients with early stage Alzheimer’s disease and who have low levels of the protein tau achieved cognitive improvement when treated with Leqembi.

Zymfentra is a subcutaneous version of infliximab.

Patients taking Mounjaro after a lifestyle intervention saw a weight reduction of almost 20%.

The increase is close to inflation and wage growth but much steeper than the atypically small increase in 2022.

Whether Opill (norgestrel) truly broadens access to daily contraception will depend on Medicaid coverage, requirements under the ACA and pharmacist prescribing.

Researchers identified age and insurance type as significant factors in viral suppression in patient with HIV because of their impact on patient adherence.

Yuflyma is on Ventegra’s public and private formulary on parity with the reference product Humira.

Insurers and PBMs now have to follow a 2020 rule in which accumulator programs can only be applied to brand name drugs that have generic equivalents available.

Inpefa is an inhibitor of both SGLT2 and SGLT1, approved to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. The wholesale acquisition cost is $598 per month.

Alnylam Pharmaceuticals will no longer pursue this indication of Onpattro and will instead on focus on a label expansion for Amvuttra, which is in phase 3 development to treat patients with cardiomyopathy of ATTR amyloidosis.

Patients who continued with their rheumatoid arthritis biologic medication tended to spend less on healthcare, had a lower chance of being hospitalized, and had shorter hospital stays.